Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
复制标题
DOI：
10.1161/circulationaha.109.933796
复制
发表时间：
2010-09-14
期刊：
影响因子：
37.8
通讯作者：
Wallentin, Lars
中科院分区：
文献类型：
--
作者：
James, Stefan;Budaj, Andrzej;Wallentin, Lars
肾功能降低与急性冠脉综合征患者预后不良和出血风险增加相关，因此可能改变抗血小板治疗的风险-获益比。在血小板抑制和患者结局（PLATO）试验中，与氯吡格雷相比，替格瑞洛降低了12个月时心血管死亡、心肌梗死和卒中的主要复合终点，但大出血率相似。（81.9%）急性冠脉综合征患者基线时，肌酐清除率，估计由Cockcroft Gault方程，计算。慢性肾脏疾病患者（肌酐清除率
Background-Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced the primary composite end point of cardiovascular death, myocardial infarction, and stroke at 12 months but with similar major bleeding rates.Methods and Results-Central laboratory serum creatinine levels were available in 15 202 (81.9%) acute coronary syndrome patients at baseline, and creatinine clearance, estimated by the Cockcroft Gault equation, was calculated. In patients with chronic kidney disease (creatinine clearance